Michael K. Gibson MD, PhD

Articles

Checkpoint Inhibitors In GC/GEJC: Trials Across the Landscape

July 11th 2025

Panelists discuss how other immunotherapy trials in the perioperative setting, including studies with pembrolizumab and atezolizumab, have shown mixed results, with improved pathologic responses not necessarily translating to survival benefits. They note the negative results from the adjuvant CheckMate 577 trial.

Surgical Considerations With IO In Perioperative GC/GEJC

July 11th 2025

Panelists discuss how adding immunotherapy (IO) to perioperative chemotherapy does not appear to complicate surgical procedures or compromise the ability to achieve negative margins, with R0 resection rates remaining unchanged between treatment arms in the MATTERHORN trial.

Interpreting MATTERHORN: Perspectives on Perioperative Durvalumab + FLOT in GC/GEJC

July 2nd 2025

Panelists discuss how the MATTERHORN results represent a practice-changing advancement that they are ready to implement clinically, with improved pathologic complete response rates and event-free survival providing confidence in the regimen’s efficacy across most patient subgroups except those with microsatellite instability–high (MSI-H) tumors.

Key Updates From MATTERHORN: Perioperative Durvalumab + FLOT in GC/GEJC

July 2nd 2025

Panelists discuss how the MATTERHORN trial successfully demonstrated that adding durvalumab immunotherapy to perioperative FLOT chemotherapy significantly improved event-free survival with an 8-percentage point improvement at 24 months, representing a clear advancement in the treatment paradigm.

Perioperative Therapy In GC/GEJC: Challenges and Unmet Needs

June 25th 2025

Panelists discuss how perioperative FLOT chemotherapy has simplified treatment decisions but presents toxicity challenges for patients with comorbidities, while emphasizing the critical importance of laparoscopic staging and acknowledging that current approaches still fail to cure approximately half of patients.

Understanding GC/GEJC: Disease Overview and Current Treatment Practices

June 25th 2025

Panelists discuss how gastric cancers (GC) and gastroesophageal junction cancers (GEJC) present with nonspecific symptoms, affect approximately 1.2 million patients worldwide annually, and are managed with perioperative FLOT chemotherapy as the established standard of care for resectable disease.

Dr Gibson on Addressing Remaining Unmet Needs in GI Cancers

June 2nd 2023

Michael K. Gibson MD, PhD, discusses the importance of addressing unmet needs related to treatment for patients with gastrointestinal cancers.

Dr Gibson on Advancements in Biomarker Identification in Gastric/GEJ Adenocarcinoma

May 15th 2023

Michael K. Gibson MD, PhD, discusses advancements in the identification of key biomarkers for patients with gastric or gastroesophageal junction adenocarcinoma, and the subsequent development of biomarker-driven therapeutics in this disease space.

Dr Gibson on Current and Emerging Biomarkers in Gastric/GEJ Adenocarcinoma

May 11th 2023

Michael K. Gibson MD, PhD, discusses current and emerging biomarkers in the treatment of patients with gastric or gastroesophageal junction adenocarcinoma.

x